Scholarlink

Introduction <p>This study assessed whether early weight loss following tirzepatide treatment was associated with clinical characteristics and outcomes at 52&#xa0;weeks in Japanese patients with type&#xa0;2 diabetes (T2D).</p> Methods <p>Post hoc analyses used pooled data from the phase&#xa0;3 SURPASS J-mono and J-combo studies, which examined tirzepatide 5, 10, and 15&#xa0;mg as monotherapy or combination therapy in Japanese participants over 52&#xa0;weeks. Subgroup analyses of clinical characteristics and metabolic outcomes at 52&#xa0;weeks were conducted based on early weight loss achievement of &lt; 5% or ≥ 5% after 8&#xa0;weeks of tirzepatide (comprising 4&#xa0;weeks each at 2.5&#xa0;mg and 5&#xa0;mg, per dose-escalation scheme). Selected safety outcomes were evaluated by weight-loss subgroups.</p> Results <p>The analysis included 893 participants (&lt; 5% subgroup: <i>n</i> = 683 [76.5%]; ≥ 5% subgroup: <i>n</i> = 210 [23.5%]). Multivariate regression analysis showed that participant clinical characteristics, including lower baseline weight, concomitant alpha-glucosidase inhibitor use, and lack of concomitant sulfonylurea use, were independently predictive of achieving ≥ 5% weight loss at 8&#xa0;weeks. Clinically significant reductions with tirzepatide were observed in body mass parameters over 52&#xa0;weeks in both subgroups, with greater weight reductions observed at week&#xa0;52 in the ≥ 5% subgroup versus the &lt; 5% subgroup (5&#xa0;mg: − 13.8% vs. − 4.1%; 10&#xa0;mg: − 16.5% vs. − 8.8%; 15&#xa0;mg: − 20.0% vs. − 11.5% [<i>p</i> &lt; 0.001, all comparisons]). Blood pressure and lipid level improvements were also significantly greater in the ≥ 5% subgroup. Improvements in glycated hemoglobin were similar between subgroups; however, the ≥ 5% subgroup had a higher proportion of participants who achieved normoglycemia at week&#xa0;52 with a shorter time to reach normoglycemia. Tirzepatide was generally well tolerated across the weight-loss subgroups.</p> Conclusions <p>These findings suggest early weight loss following tirzepatide may be predictive of metabolic outcomes at 52&#xa0;weeks in Japanese patients with T2D. These data may inform clinical management of tirzepatide-treated patients.</p> ClinicalTrials.gov <p>NCT03861052, NCT03861039.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Hanaka Mimura,
  • Tomonori Oura,
  • Rina Chin,
  • Tetsuaki Hirase,
  • Dai Shimono

摘要

Introduction

This study assessed whether early weight loss following tirzepatide treatment was associated with clinical characteristics and outcomes at 52 weeks in Japanese patients with type 2 diabetes (T2D).

Methods

Post hoc analyses used pooled data from the phase 3 SURPASS J-mono and J-combo studies, which examined tirzepatide 5, 10, and 15 mg as monotherapy or combination therapy in Japanese participants over 52 weeks. Subgroup analyses of clinical characteristics and metabolic outcomes at 52 weeks were conducted based on early weight loss achievement of < 5% or ≥ 5% after 8 weeks of tirzepatide (comprising 4 weeks each at 2.5 mg and 5 mg, per dose-escalation scheme). Selected safety outcomes were evaluated by weight-loss subgroups.

Results

The analysis included 893 participants (< 5% subgroup: n = 683 [76.5%]; ≥ 5% subgroup: n = 210 [23.5%]). Multivariate regression analysis showed that participant clinical characteristics, including lower baseline weight, concomitant alpha-glucosidase inhibitor use, and lack of concomitant sulfonylurea use, were independently predictive of achieving ≥ 5% weight loss at 8 weeks. Clinically significant reductions with tirzepatide were observed in body mass parameters over 52 weeks in both subgroups, with greater weight reductions observed at week 52 in the ≥ 5% subgroup versus the < 5% subgroup (5 mg: − 13.8% vs. − 4.1%; 10 mg: − 16.5% vs. − 8.8%; 15 mg: − 20.0% vs. − 11.5% [p < 0.001, all comparisons]). Blood pressure and lipid level improvements were also significantly greater in the ≥ 5% subgroup. Improvements in glycated hemoglobin were similar between subgroups; however, the ≥ 5% subgroup had a higher proportion of participants who achieved normoglycemia at week 52 with a shorter time to reach normoglycemia. Tirzepatide was generally well tolerated across the weight-loss subgroups.

Conclusions

These findings suggest early weight loss following tirzepatide may be predictive of metabolic outcomes at 52 weeks in Japanese patients with T2D. These data may inform clinical management of tirzepatide-treated patients.

ClinicalTrials.gov

NCT03861052, NCT03861039.